36 results about "Paenibacillus lactis" patented technology

The invention comprises a substrate for detection of micro-organisms, wherein said substrate comprises a set of molecular markers linked, optionally with linker molecules or moeieties, to a di-, or tripeptide consisting of amino acids X1 and X2, or X1, X2 and X3, in which one of them, for example X1, is a D-amino acid and the others, for example X2 and X3, may be any D- or L-amino acid. Said substrate preferably is used for the detection of Bacillus anthracis. Alternatively, the invention is directed to a substrate for detection of micro-organisms, more specifically P. aeruginosa, wherein said substrate comprises a set of molecular markers linked, optionally with linker molecules or moeities to a tri- tetra or pentapeptide consisting of glycine amino acids. The invention further comprises methods for detection of micro-organisms, specifically Bacillus anthracis and Pseudomonas aeruginosa, with the substrates of the invention and use of the substrate(s) in such a method.

A variety of modified Bacillus anthracis bacteria useful in vaccines are provided. For instance, asporogenic strains of Bacillus anthracis are provided. In addition, Bacillus anthracis strains attenuated in their ability to repair their nucleic acid, such as in their nucleic acid excision repair ability or recombination repair ability, are provided. Strains expressing an antigen, such as protective antigen, under the control of a heterologous promoter and/or an inducible promoter are also provided. Bacillus anthracis bacteria comprising mutations in toxin genes are further provided. Vaccine compositions comprising the bacteria, methods of making the modified strains, and methods of using the vaccines are also provided.

Immunogenic compositions and kits, as well as methods of stimulating immune responses and methods of immunization using the same. The compositions and kits comprise: (a) an antigen derived from Bacillus anthracis; (b) polymer microparticles comprising a biodegradable polymer; and (c) a polynucleotide-containing immunological adjuvant.

The present invention presents the isolation, characterization and synthesis of oligosaccharides of Bacillus anthracis. Also presented are antibodies that bind to such saccharide moieties and various methods of use for such saccharide moieties and antibodies.

Methods of preparing and using natural or synthetic zeolitic compositions therapeutically to alleviate, cure, or even preclude human host indisposition from exposure to bacteria within the Bacillus anthracis group: namely, B. anthracis, B. cereus, B. Mycoides, and B. thurigiensis. Exposure to bacilli of the first member of that group causes the often fatal disease anthrax.

The present invention is directed to novel pharmaceutical compositions and methods of inhibiting or blocking one or more virulence antigenic factors of multiple strains of Bacillus anthracis in an individual. Specifically, it involves the administering of an expression vector alone or in conjunction with a fusion protein. The expression vector has a transcription unit encoding a fusion protein composed of an antigenic factor of Bacillus anthracis or fragment thereof attached via a linker to the aminoterminal end of the CD40 ligand. This fusion protein has the ability to generate antibodies and/or cytotoxic T cells which inhibit or block Bacillus anthracis infection in an individual.

The invention provides a heterogeneous immunoassay for detection of antibodies and antigens based on specific antigen-antibody immune complex formation with multiple antigen-bearing conjugate components. The invention further provides means for optimizing the assay format for the detection of both low and high-affinity antibodies, and provides means for quantitative detection of both antibody and the corresponding antigen present in a sample. In preferred embodiments, the invention can be practiced to detect presence in biological fluid samples of antibodies to Bacillus anthracis related antigens.

Production of protein conjugate vaccines by use of transpeptidase enzymes, such as sortase enzymes. For example, homogenous immunoconjugates (e.g., a population of molecules having the same structure) formed by conjugating an antigenic polypeptide and a bacterial capsule component are provided. In certain aspects, methods for generating an immune response to B. anthracis by use of protective antigen-PDGA immunoconjugates are provided.

The invention discloses a chemically modified base-containing single-stranded DNA aptamer capable of specifically recognizing anthrax protective antigen PA83 and application thereof. According to thechemically modified base-containing single-stranded DNA aptamer, the anthrax protective antigen (PA83) is taken as a target, a nucleic acid library containing chemically modified nucleotides is utilized, a high-affinity aptamer AP5 is screened out by a paramagnetic particle method SELEX, and the aptamer can specifically recognize PA83 protein in the environment of various interference proteins; the aptamer can be applied to an aptamer biosensor based on a surface plasmon resonance technology and a fluorescence polarization technology and used for detecting PA83 protein so as to detect bacillusanthracis, and the aptamer has the potential of being applied to construction of a novel bacillus anthracis protective antigen detection technology.

Exemplary methods and systems for killing or deactivating spores include applying a fluid to a surface containing a spore; and applying direct or indirect plasma to the surface for a period of time. In some embodiments, the fluid includes water. In some embodiments, the spore is Clostridium difficile and in some is Bacillus Anthracis. In some embodiments, the fluid is in the form of a mist and in some is in the form of a vapor. In some embodiments, peroxynitrite is created in the fluid during the method. Another exemplary embodiment of killing or deactivating a spore includes treating spores with direct plasma or an indirect plasma for a period of time and applying an antimicrobial to the spores. In some embodiments, the antimicrobial is an alcohol, a bleach or an alcohol-based sanitizer.

The present invention relates to peptides that bind to the bacterial spores, such as B. anthracis, B. subtilis and B. cereus spores. The present invention also relates to method of identifying such peptides using phage display ligand screening system. The present invention further relates to the use of such peptides for the detection of bacterial spores, such as Bacillus anthracis spores.

The invention provides a bacillus anthracis detection kit. The bacillus anthracis detection kit comprises two pairs of primers using bacillus anthracis PA genes as target genes and designed on the basis of a loop-mediated isothermal amplification technology, namely inner primers FIP/BIP and outer primers F3/B3. The bacillus anthracis detection kit has more comprehensive detection effect and low omission rate.

The invention relates to spore specific antibodies. Compositions and methods relating to the antibodies are provided along with the hybridomas that produce the antibodies. The antibodies are specific for the spores of B. anthracis relative to the vegetative form of the cells. The antibodies are also specific for the spores relative to other Bacillus spores and cells. The antibodies may be used to detect the presence of B. anthracis spores by use of methods provided herein. The invention also relates to articles of manufacture as well as kits comprising these antibodies which may be used in the detection methods of the invention.

The invention includes compositions and methods of detection of Bacillus anthracis that use oligonucleotide probes specific for genetic material contained in the pXO1 and pXO2 plasmids in nucleic acid hybridization reactions. Embodiments of the method may include additional probes specific for other gene sequences to distinguish B. anthracis from other bacterial species present in a sample or to provide an indication that the assay was performed properly even when no Bacillus sequence is detected.

Regions of Bacillus anthracis protective antigen are provided representing epitopes recognized by antibodies in subjects that have acquired immunity to Bacillus anthracis infection. The recognition of these epitopes correlates with autoimmunity in a subject. Also provided are vaccines that include at least one of these epitopes that when administered to a subject provide improved acquired immunity.

This disclosure generally relates to therapeutic antibodies for treating Bacillus anthracis (B. anthracis) infection, to specific variants thereof, pharmaceutical composition comprising them and to methods for their use.